Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | GRM1 | Q13255 | 5/20 | 0.53 |
| ▸ | DPP4 | P27487 | 3/20 | 0.53 |
| ▸ | GRM5 | P41594 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2117294 | 0.91 | DPP4 (0.57) | TP53MAPTNPSR1GRM1DPP4 | |
| SCHEMBL2117289 | 0.89 | TP53 (0.69) | TP53MAPTNPSR1GRM1DPP4 | |
| SCHEMBL1753296 | 0.86 | TP53 (0.78) | TP53MAPTNPSR1GRM1GRM5 | |
| SCHEMBL2115393 | 0.85 | MAPT (0.64) | TP53MAPTNPSR1GRM1DPP4 | |
| SCHEMBL1753212 | 0.84 | TP53 (0.67) | TP53MAPTNPSR1GRM1GRM5 | |
| SCHEMBL2119212 | 0.84 | TP53 (0.75) | TP53MAPTNPSR1GRM1DPP4 | |
| SCHEMBL1753227 | 0.83 | TP53 (0.66) | TP53MAPTNPSR1GRM1DPP4 | |
| SCHEMBL1753542 | 0.83 | GRM1 (0.69) | TP53MAPTNPSR1GRM1GRM5 | |
| SCHEMBL1753240 | 0.83 | TP53 (0.62) | TP53MAPTNPSR1GRM1DPP4 | |
| SCHEMBL1753239 | 0.83 | GRM1 (0.69) | TP53MAPTNPSR1GRM1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158634-B2 | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | IRM LLC (BM) | 2012-04-17 | — | — | US | claimed |
| US-20120225869-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2012-09-06 | — | — | US | disclosed |
| US-8158634-B2 | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | IRM LLC (BM) | 2012-04-17 | — | — | US | disclosed |
| US-20090247517-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2009-10-01 | — | — | US | disclosed |
| US-20070299047-A1 | Combination of Organic Compounds | MAHER WILLIAM | 2007-12-27 | — | — | US | disclosed |
| EP-1791600-A1 | COMBINATION OF ORGANIC COMPOUNDS | Novartis AG (CH) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006029349-A1 | COMBINATION OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299047-A1 | Combination of Organic Compounds | GLP1R, PPARG, GCGR | TP53 4351/4885MAPT 4328/4885NPSR1 391/4885 |
| US-20120225869-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | CNR1, CNR2, FAAH | TP53 4640/4885MAPT 1780/4885NPSR1 92/4885 |
| US-20090247517-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | CNR1, CNR2, FAAH | TP53 4640/4885MAPT 1780/4885NPSR1 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.